Novo Nordisk’s newly approved version of Wegovy will be available in U.S. self-pay channels in January, priced at $149 a month for Medicare, Medicaid, and cash-paying customers. The weight-loss pill will test the cash-paying consumer market, part of a deal with the Trump administration. This news was reported by Maggie Fick of Reuters.

Read more at Yahoo Finance: Novo’s Wegovy pill is planned to enter U.S. self-pay channels, Reuters says